These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 32727745)
1. From blockbuster to "nichebuster": how a flawed legislation helped create a new profit model for the drug industry. Marselis D; Hordijk L BMJ; 2020 Jul; 370():m2983. PubMed ID: 32727745 [No Abstract] [Full Text] [Related]
2. Generic Competition for Drugs Treating Rare Diseases. Beall RF; Quinn AE; Kesselheim AS; Tessema FA; Sarpatwari A J Law Med Ethics; 2020 Dec; 48(4):789-795. PubMed ID: 33404340 [No Abstract] [Full Text] [Related]
3. Orphan drug pricing may warrant a competition law investigation. Roos JC; Hyry HI; Cox TM BMJ; 2010 Nov; 341():c6471. PubMed ID: 21081598 [No Abstract] [Full Text] [Related]
4. Does orphan drug legislation really answer the needs of patients? Haffner ME; Torrent-Farnell J; Maher PD Lancet; 2008 Jun; 371(9629):2041-4. PubMed ID: 18555916 [No Abstract] [Full Text] [Related]
5. EU to review rare disease drugs market exclusivity. Sheridan C Nat Biotechnol; 2004 Sep; 22(9):1061. PubMed ID: 15340455 [No Abstract] [Full Text] [Related]
8. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
9. Open letter to prime minister David Cameron and health secretary Andrew Lansley. Nicholl DJ; Hilton-Jones D; Palace J; Richmond S; Finlayson S; Winer J; Weir A; Maddison P; Fletcher N; Sussman J; Silver N; Nixon J; Kullmann D; Embleton N; Beeson D; Farrugia ME; Hill M; McDermott C; Llewelyn G; Leonard J; Morris M BMJ; 2010 Nov; 341():c6466. PubMed ID: 21081599 [No Abstract] [Full Text] [Related]
10. Promoting the development of drugs against rare diseases: what more should be done? Westermark K; Llinares J Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):541-3. PubMed ID: 23186396 [No Abstract] [Full Text] [Related]
11. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy. Liu BC; He L; He G; He Y J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648 [TBL] [Abstract][Full Text] [Related]
12. [Authorization and reimbursement of orphan drugs in an international comparison]. Roll K; Stargardt T; Schreyögg J Gesundheitswesen; 2011 Aug; 73(8-9):504-14. PubMed ID: 20848380 [TBL] [Abstract][Full Text] [Related]
13. The challenges of orphan drugs and orphan diseases: real and imagined. Hudson I; Breckenridge A Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659 [TBL] [Abstract][Full Text] [Related]
20. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017. Guan X; Zhang J; Man C; Ni B; Shi L J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]